Astellas Pharma Inc.

4503

JP3942400007

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Sector

Pharmaceuticals

Calendar

29/07/2024 - Q1 2024 Earnings Release (Projected)

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,544 JPY

Average target price

2,009 JPY

Spread / Average Target

+30.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTELLAS PHARMA INC.	-8.39%	18.14B
ELI LILLY AND COMPANY	+33.22%	700B
JOHNSON & JOHNSON	-4.94%	358B
MERCK & CO., INC.	+18.99%	330B
ABBVIE INC.	+3.67%	287B
ASTRAZENECA PLC	+15.70%	236B
NOVARTIS AG	+6.68%	202B
ROCHE HOLDING AG	-9.08%	197B
AMGEN INC.	+6.42%	161B
PFIZER, INC.	-1.68%	157B

Other Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 08/05/2024 BST			5-day change	1st Jan Change
1,544 ^JPY	-1.15%		+2.01%	-8.39%

05:39pm	Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	CI
05-02	Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	MT

Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	04:39pm	CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	05-02	MT
Malin Corp investee signs agreement with Astellas Pharma	05-01	AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	05-01	DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	04-30	RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024	04-25
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024	04-25	CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024	04-25	CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	04-25	CI
Astellas Pharma Inc. Announces Board and Committee Retirements	04-25	CI
European Commission Approves Astellas Pharma Label Extension for Xtandi	04-25	MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	04-24	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	04-22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	04-22	CI
Lupin Launches Mirabegron Extended-Release Tablets in US	04-22	MT
Japan Inc makes a renewed U.S. push as China fears mount	04-17	RE
Middle East Tensions Blunt Asian Stock Markets Excepting China	04-15	MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	04-15	MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	04-15	RE
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	04-15	RE
Astellas Pharma Inc. Provides Impairment Loss for Intangible Assets Guidance for the Fourth Quarter 2023	04-12	CI
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	04-12	CI
Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy	04-03	MT
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy	04-01	CI
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China	03-28	MT